| For Immediate Release | 18 February 2021 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Preliminary Results,
Analyst Conference Call and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021.
A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at alliancepharma@buchanan.uk.com.
A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link:
https://webcasting.buchanan.uk.com/broadcast/60180f8da6bfbf43d06ac2ea
The recorded webcast will also be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/.
For more information, please contact Buchanan on 020 7466 5000 or email alliancepharma@buchanan.uk.com.
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Peter Butterfield, Chief Executive Officer |
|
| Andrew Franklin, Chief Financial Officer |
|
| www.alliancepharma.co.uk |
|
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills / Hannah Ratcliff |
|
| alliancepharma@buchanan.uk.com
|
|
| Numis Securities Limited | + 44 (0)20 7260 1000 |
| Nominated Adviser: Freddie Barnfield / Huw Jeremy |
|
| Corporate Broking: James Black |
|
| Investec Bank plc | + 44 (0)20 7597 5970 |
| Corporate Finance: Daniel Adams |
|
| Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
